SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
InterMune (nasdaq)ITMN
An SI Board Since March 2000
Posts SubjectMarks Bans Symbol
508 36 0 ITMN
Emcee:  Secret_Agent_Man Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
308<i>Intermune sold off hard immediately after the breakout session ended (Biomaven-9/6/2002
307"Shorts, longs fight over Intermune Adam Feuerstein 9-05-02 04:08 PM EDT IRWIN JAMES FRANKEL-9/5/2002
306Trial design is always easy in retrospect. Kind of like investing. :) That saidBiomaven-9/4/2002
305I think itmn did as best as could be expected given the very limited data and prrkrw-9/3/2002
304Thanks. What I found most surprising was the description of the poor design of ttom pope-9/3/2002
303Useful commentary on Feuerstein article by a poster on Yahoo called "phudocRCMac-9/3/2002
302That's just an independent (of itmn) physician led study. At most itmn wouldrkrw-9/3/2002
301Note this contrast: "Strieter has no financial ties to Intermune and doesnIRWIN JAMES FRANKEL-9/3/2002
300I agree. A 40% survival advantage was impressive and not trivial at all. I thirkrw-9/3/2002
299Good article. Although he probably should have pointed out that there was a strMichael Young-9/3/2002
298Intermune Is Biotech's New Battleground By Adam Feuerstein Senior Writer 0rkrw-9/3/2002
297Results at CHEST will be very interesting to dissect, trying to unravel the seemquidditch-8/29/2002
296That was simply so cool, seeing it open slightly DOWN on the news. I was madly scaram(o)uche-8/28/2002
29518.1 million shares traded .5 million shares of Sept calls traded 1.0 million sIRWIN JAMES FRANKEL-8/28/2002
294FWIW, from Briefing.com, >>11:06AM InterMune estimates cut by Lehman (ITMtuck-8/28/2002
293quid, This is a very interesting issue - why the improved mortality given not mBiomaven-8/28/2002
292Thanks, Peter. Did you buy management's answer (Harkonen passed the questioquidditch-8/28/2002
291quid, I think we might well see statistical significance for mortality for the Biomaven-8/28/2002
290A key question on the CC was something to the effect of "Can you achieve thtuck-8/28/2002
289Conference call: With Harkonen's response to one of the last questions abouquidditch-8/28/2002
288InterMune Announces Phase III Data Demonstrating Survival Benefit Of Actimmune imichael_f_murphy-8/28/2002
287<<Does today's 11+ % drop make anyone nervous.>> Sure did. Notrkrw-8/27/2002
286>>Does today's 11+ % drop make anyone nervous.<< A bit. As doetuck-8/27/2002
285Does today's 11+ % drop make anyone nervous.jayhawk969-8/27/2002
284InterMune to Hold Conference Call to Discuss Phase III Clinical Trial Results OfIRWIN JAMES FRANKEL-8/27/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News